- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02092896
Liraglutide as add-on to Insulin in Type 1 Diabetes (T1DMLIRA)
Treatment With Liraglutide as add-on to Insulin in Type 1 Diabetic Patients. Effects on Glycemic Control and Counterregulation and Cognitive Performance During Hypoglycaemia
The purpose of this study is to:
Part 1:
To investigate how 12 weeks treatment with liraglutide affects glycemic control in poorly controlled patients and how the treatment affects gastric emptying rate during hypoglycemia.
Part 2:
To investigate how 12 weeks treatment of type 1 diabetic patients with liraglutide affects counterregulatory hormones and cognitive performance during hypoglycemia.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
Copenhagen
-
Hvidovre, Copenhagen, Dänemark, 2650
- Dept. of Endocrinology, Hvidovre University Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age: 18-70 years
- BMI: 18-28
- HbA1c ≥ 8 %
- No residual β-cell function (glucagon test with c-peptide < 60 pM)
- Caucasian
- Diagnosed with type 1 diabetes at 5 to 40 years of age (both inclusive).
- Remission phase must be completed
- Female participants must use adequate contraception
- Informed consent
Exclusion Criteria:
- Overt diabetes complications; creatinin > 130 µM, proliferative retinopathy, macroalbuminuria.
- Autonomic neuropathy (RR-variation </=10 beats/min) and/or Orthostatic hypotension (OH).
- Anemia, Hb concentration; female <7.0 mmol/l, male<8.0 mmol/l
- Pregnancy or lactation
- Epilepsy
- Use of antiepileptic medication
- Use of beta blockers
- Previously apoplexy cerebri.
- Any use of benzodiazepine within the last month
- Any use of neuroleptic drugs within the last six months
- Self-perceived hearing loss
- Alcohol or drug abuse
- Allergy to the medication or placebo.
- Treatment with any medication affecting glucose metabolism.
- Any disorder which in the investigators opinion could interfere with the safety and results of the trial
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Placebo-Komparator: Placebo + Insulin + Study 2
Study 2: Cognitive performance test
|
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks.
At baseline and week 12 study 1 is performed.
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks.
At baseline and week 12 study 2 is performed.
|
|
Experimental: Liraglutide + Insulin + Study 2
Study 2: Cognitive performance test
|
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks.
At baseline and week 12 study 1 is performed.
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks.
At baseline and week 12 study 2 is performed.
|
|
Experimental: Liraglutide + Insulin + Study 1
Study 1: Gastric emptying test
|
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks.
At baseline and week 12 study 1 is performed.
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks.
At baseline and week 12 study 2 is performed.
|
|
Placebo-Komparator: Placebo + Insulin + Study 1
Study 1: Gastric emptying test
|
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks.
At baseline and week 12 study 1 is performed.
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks.
At baseline and week 12 study 2 is performed.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Change from baseline in HbA1c (glycosylated haemoglobin)
Zeitfenster: Week 0, week 12
|
Week 0, week 12
|
|
Changes from baseline in EEG and cognitive performances
Zeitfenster: week 0, week 12
|
week 0, week 12
|
|
Change from baseline in gastric emptying rate
Zeitfenster: week 0, week 12
|
week 0, week 12
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Change from baseline in glycemic control (CGM)
Zeitfenster: week 0, week 12
|
week 0, week 12
|
|
Change from baseline in total daily insulin dose
Zeitfenster: week 0, week 12
|
week 0, week 12
|
|
Changes from baseline in the counterregulatory hormone responses during hypoglycemia
Zeitfenster: week 0, week 12
|
week 0, week 12
|
|
Change from baseline in body weight
Zeitfenster: week 0, week 12
|
week 0, week 12
|
|
Change from baseline in auditory evoked potentials (AEP) during hypoglycemia
Zeitfenster: week 0, week 12
|
week 0, week 12
|
|
Change from baseline in corrected QTc-interval (QTc) during hypoglycemia
Zeitfenster: week 0, week 12
|
week 0, week 12
|
|
Change from baseline in hypoglycemic symptom score
Zeitfenster: week 0, week 12
|
week 0, week 12
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Frequency of Hypoglycemic episodes
Zeitfenster: Week 0, week 12
|
Week 0, week 12
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Christian SS Frandsen, MD, Hvidovre University Hospital
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Störungen des Glukosestoffwechsels
- Stoffwechselerkrankungen
- Erkrankungen des Immunsystems
- Autoimmunerkrankungen
- Erkrankungen des endokrinen Systems
- Diabetes Mellitus
- Diabetes mellitus, Typ 1
- Hypoglykämische Mittel
- Physiologische Wirkungen von Arzneimitteln
- Hormone
- Hormone, Hormonersatzstoffe und Hormonantagonisten
- Inkretine
- Liraglutid
Andere Studien-ID-Nummern
- 2012-002526-67 (EudraCT-Nummer)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .